HORIZON-PFT
Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly
Paciente / Población Intervención / Exposición Comparación Desenlace
In 7,765 postmenopausal women with osteoporosis, annual intravenous zoledronic acid 5 mg reduced new vertebral and hip fractures compared with placebo.
N
7765
Diseño
Double-blind RCT, 3 yr
Desenlace
New morphometric vertebral fracture
Relevancia
2
ResultadoVertebral fracture RR 0.30 (p<0.001); hip fracture HR 0.59 (−41 %; p=0.002).
Black DM, et al. N Engl J Med. 2007;356(18):1809-1822. 10.1056/NEJMoa067312
Discusión y crítica
Established annual intravenous bisphosphonate dosing — the option for patients intolerant of oral therapy or with adherence concerns.